{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:21:30Z","timestamp":1791019290280,"version":"4.1.0"},"reference-count":195,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["K12-EY016335"],"award-info":[{"award-number":["K12-EY016335"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01-EY12963"],"award-info":[{"award-number":["R01-EY12963"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01-EY20889"],"award-info":[{"award-number":["R01-EY20889"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jtos.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T07:06:01Z","timestamp":1621062361000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Ocular redness \u2013 II: Progress in development of therapeutics for the management of conjunctival hyperemia"],"prefix":"10.1016","volume":"21","author":[{"given":"Rohan Bir","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-2364","authenticated-orcid":false,"given":"Ann","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7497-0681","authenticated-orcid":false,"given":"Sonia","family":"Anchouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad K.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-117X","authenticated-orcid":false,"given":"Tomas","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-4541","authenticated-orcid":false,"given":"Thomas H.","family":"Dohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1340-6758","authenticated-orcid":false,"given":"Jia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-5100","authenticated-orcid":false,"given":"Reza","family":"Dana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2021.05.004_bib1","doi-asserted-by":"crossref","DOI":"10.5811\/westjem.2016.12.31798","article-title":"Differentiating urgent and emergent causes of acute red eye for the emergency physician","author":"Gilani","year":"2017","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.jtos.2021.05.004_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.mcna.2016.12.013","article-title":"Ocular emergencies: red eye","volume":"101","author":"Tarff","year":"2017","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jtos.2021.05.004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pop.2015.05.002","article-title":"Approach to red eye for primary care practitioners","author":"Dunlop","year":"2015","journal-title":"Prim Care Clin Off Pract"},{"key":"10.1016\/j.jtos.2021.05.004_bib4","first-page":"6","article-title":"Vasoconstrictors\u00a0: myths and Realities the facts about how vasoconstrictors work and thoughts about mechanisms behind their purported negative side effects","author":"Abelson","year":"2015","journal-title":"Rev Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/OPX.0000000000001182","article-title":"Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: a randomized clinical trial","volume":"95","author":"McLaurin","year":"2018","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1046\/j.1398-9995.2003.00326.x","article-title":"Animal models of allergic and inflammatory conjunctivitis","volume":"58","author":"Groneberg","year":"2003","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib7","first-page":"451","article-title":"Models of immediate and delayed hypersensitivity in the Guinea pig conjunctiva","volume":"91","author":"Dwyer","year":"1971","journal-title":"Trans Ophthalmol Soc U K"},{"key":"10.1016\/j.jtos.2021.05.004_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/02713689509003760","article-title":"Experimental model of allergic conjunctivitis to ragweed in Guinea pig","volume":"14","author":"Merayo-Lloves","year":"1995","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1248\/bpb.23.566","article-title":"Experimental allergic conjunctivitis in Guinea pigs induced by Japanese cedar pollen","volume":"23","author":"Takada","year":"2000","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jtos.2021.05.004_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000232744","article-title":"Immediate hypersensitivity in the Guinea pig conjunctiva. III. Long-term persistence of the hypersensitive state and characterization of antibodies","volume":"65","author":"Dwyer","year":"1981","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/108076801750125757","article-title":"Platelet activating factor degradation in tear fluid from Guinea pigs with allergic conjunctivitis","volume":"17","author":"Kato","year":"2001","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib12","first-page":"2281","article-title":"Histamine and prostacyclin: primary and secondary release in allergic conjunctivitis","volume":"32","author":"Helleboid","year":"1991","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib13","first-page":"637","article-title":"Role of substance P in experimental allergic conjunctivitis in Guinea pigs","volume":"19","author":"Yamaji","year":"1997","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI200315937","article-title":"Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis","volume":"111","author":"Sohn","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtos.2021.05.004_bib15","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/ICO.0b013e3181a18acd","article-title":"Image analyses of the kinetic changes of conjunctival hyperemia in histamine-induced conjunctivitis in Guinea pigs","volume":"28","author":"Fukushima","year":"2009","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2021.05.004_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1081-1206(10)63498-9","article-title":"Efficacy of nedocromil sodium and cromolyn sodium in an experimental model of ocular allergy","volume":"77","author":"Calonge","year":"1996","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF02153399","article-title":"The ability of salbutamol and theophylline to suppress immediate allergic conjunctivitis in the Guinea pig","volume":"225","author":"Gautheron","year":"1987","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(24)29398-8","article-title":"Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751","volume":"298","author":"Arimura","year":"2001","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1139\/y89-132","article-title":"Immediate hypersensitivity reactions in the Guinea-pig conjunctiva: studies with a second-generation leukotriene D4 receptor antagonist, MK-571","volume":"67","author":"Chan","year":"1989","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0014-2999(87)90359-1","article-title":"The role of leukotriene D4 as a mediator of allergic conjunctivitis in the Guinea-pig","volume":"134","author":"Garceau","year":"1987","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0021-5155(01)00365-3","article-title":"Immunosuppressive effect of cholera toxin B on allergic conjunctivitis model in Guinea pig","volume":"45","author":"Saito","year":"2001","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1590\/S0102-695X2011005000145","article-title":"Chalcones from Myracrodruon urundeuva are efficacious in Guinea pig ovalbumininduced allergic conjunctivitis","volume":"21","author":"de Mendon\u00e7a Albuquerque","year":"2011","journal-title":"Braz J Pharmacogn"},{"key":"10.1016\/j.jtos.2021.05.004_bib23","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/bjo.86.10.1166","article-title":"Exertion of the suppressive effects of IFN-\u03b3 on experimental immune mediated blepharoconjunctivitis in Brown Norway rats during the induction phase but not the effector phase","volume":"86","author":"Fukushima","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1046\/j.1365-2249.2000.01319.x","article-title":"Effects of IL-4 and IL-2 on experimental immune-mediated blepharoconjunctivitis in Brown Norway rats","volume":"122","author":"Ozaki","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s004170050363","article-title":"Experimental immune-mediated blepharoconjunctivitis in rats induced by immunization with ragweed pollen","volume":"238","author":"Iwamoto","year":"2000","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000068551","article-title":"Comparison of antiallergic drugs in an experimental model of ocular anaphylaxis","volume":"217","author":"Bayer","year":"2003","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jtos.2021.05.004_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF02868026","article-title":"Nedocromil sodium in two models of conjunctival immediate hypersensitivity","volume":"17","author":"McGrath","year":"2000","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2021.05.004_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1248\/bpb.28.473","article-title":"Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats","volume":"28","author":"Minami","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jtos.2021.05.004_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s004170050252","article-title":"Inhibitory effects of FK506 on the development of experimental allergic\/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration","volume":"237","author":"Iwamoto","year":"1999","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-001-0424-0","article-title":"Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norxway rats by topical application of FK506","volume":"240","author":"Nishino","year":"2002","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib31","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1006\/exer.1997.0362","article-title":"The role of cellular immunity both in the induction and effector phases of experimental allergic blepharoconjunctivits (EAC) in rats","volume":"65","author":"Fukushima","year":"1997","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/02713689808951255","article-title":"Characterization of the immunopathogenic responses to ovalbumin peptide 323-339 in experimental immune-mediated blepharoconjunctivitis in Lewis rats","volume":"17","author":"Fukushima","year":"1998","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib33","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s004170050171","article-title":"Comparison of genetic susceptibility to experimental allergic\/immune-mediated blepharoconjunctivitis between Lewis and Fischer vats","volume":"236","author":"Yoshida","year":"1998","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib34","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0091-6749(96)70268-3","article-title":"A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium","volume":"97","author":"Merayo-Lloves","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clin.1997.4507","article-title":"A novel murine model of allergic conjunctivitis","volume":"87","author":"Magone","year":"1998","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jtos.2021.05.004_bib36","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E","article-title":"Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis","volume":"30","author":"Magone","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clin.1997.4507","article-title":"A novel murine model of allergic conjunctivitis","volume":"87","author":"Magone","year":"1998","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jtos.2021.05.004_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxn137","article-title":"Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1\/CCR3 blockade","volume":"21","author":"Miyazaki","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib39","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.4049\/jimmunol.175.8.5489","article-title":"The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS)3 and SOCS5 in a murine model","volume":"175","author":"Ozaki","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib40","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1167\/iovs.09-3637","article-title":"Blocking mast cell-mediated type i hypersensitivity in experimental allergic conjunctivitis by monocyte chemoattractant protein-1\/CCR2","volume":"50","author":"Tominaga","year":"2009","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4049\/jimmunol.1502416","article-title":"Role of CCL7 in type I hypersensitivity reactions in murine experimental allergic conjunctivitis","volume":"198","author":"Kuo","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib42","first-page":"1966","article-title":"Curcumin suppresses ovalbumin-induced allergic conjunctivitis","volume":"18","author":"Chung","year":"2012","journal-title":"Mol Vis"},{"key":"10.1016\/j.jtos.2021.05.004_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1874364101206010129","article-title":"Levocetirizine inhibits migration of immune cells to lymph nodes and induces treg cells in a murine type I allergic conjunctivitis model","volume":"6","author":"Garcia-Zepeda","year":"2012","journal-title":"Open Ophthalmol J"},{"key":"10.1016\/j.jtos.2021.05.004_bib44","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3109\/02713683.2011.573898","article-title":"Ameliorative effect of thymoquinone on ovalbumin-induced allergic conjunctivitis in Balb\/c mice","volume":"36","author":"Hayat","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000350551","article-title":"Heparin treatment for allergic conjunctivitis in the experimental Balb\/c model","volume":"50","author":"Kocat\u00fcrk","year":"2013","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib46","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.3892\/mmr.2016.4937","article-title":"Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF","volume":"13","author":"Quan","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jtos.2021.05.004_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000267144","article-title":"Clinical and cytologic aspects of ocular late-phase reaction in the Guinea pig","volume":"24","author":"Allansmith","year":"1992","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000267102","article-title":"Double hapten challenge in Guinea pigs undergoing an ocular late-phase reaction","volume":"23","author":"Leonardi","year":"1991","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000267173","article-title":"Conjunctival mast cells and the allergic late phase reaction","volume":"24","author":"Leonardi","year":"1992","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib50","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1006\/phrs.1999.0637","article-title":"Changes in histamine content following pharmacologically-induced mast cell degranulation in the rat conjunctiva","volume":"41","author":"Tiligada","year":"2000","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib51","first-page":"264","article-title":"A hapten model of topically-induced ocular anaphylaxis in the rat","volume":"28","author":"Trocm\u00e9","year":"1987","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib52","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/02713688808997241","article-title":"Attenuation of rat conjunctival response by repeated hapten applications","volume":"7","author":"Barney","year":"1988","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/02713688809031795","article-title":"Late-phase reaction in topically induced ocular anaphylaxis in the rat","volume":"7","author":"Trocm\u00e9","year":"1988","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1755-3768.1989.tb07106.x","article-title":"Ocular anaphylaxis induced in the rat by topical application of compound 48\/80: dose response and time course study","volume":"67","author":"Allansmith","year":"1989","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0952-3278(02)00232-6","article-title":"Bimatoprost (Lumigan\u00ae) is an agonist at the cloned human ocular F.P. prostaglandin receptor: real-time FLIPR-based intracellular Ca2+ mobilization studies","volume":"68","author":"Sharif","year":"2003","journal-title":"Prostagl Leukot Essent Fat Acids"},{"key":"10.1016\/j.jtos.2021.05.004_bib56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02850114","article-title":"Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension","volume":"20","author":"Abelson","year":"2003","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2021.05.004_bib58","volume":"vol. 23","author":"Chen","year":"2005"},{"key":"10.1016\/j.jtos.2021.05.004_bib59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/OPTH.S10444","article-title":"In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in Guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%","volume":"4","author":"Ogundele","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib60","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/bbrc.1993.1451","article-title":"Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma","volume":"192","author":"Kitamura","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtos.2021.05.004_bib61","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/13892037113149990053","article-title":"Comparing the molecular pharmacology of CGRP and adrenomedullin","volume":"14","author":"Woolley","year":"2013","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0014-2999(00)00376-9","article-title":"Adrenomedullin and ocular inflammation in the rabbit","volume":"400","author":"Clementi","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib63","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0886-3350(13)80412-9","article-title":"Intraocular dapiprazole for the reversal of mydriasis after extracapsular cataract extraction with intraocular lens implantation: Part II: comparison with acetylcholine","volume":"17","author":"Ponte","year":"1991","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.jtos.2021.05.004_bib64","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/bjo.2006.112680","article-title":"Sensitivity and reliability of objective image analysis compared to subjective grading of bulbar hyperaemia","volume":"91","author":"Peterson","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib65","first-page":"125","article-title":"Prostaglandins and inflammation in the eye","volume":"16","author":"Nelson","year":"1976","journal-title":"Mod Probl Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib66","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archopht.1980.01020030850009","article-title":"Effects of ocular decongestants","volume":"98","author":"Abelson","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib67","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF03022319","article-title":"Alpha-adrenergic mRNA subtype expression in the human nasal turbinate","volume":"54","author":"Stafford-Smith","year":"2007","journal-title":"Can J Anesth"},{"key":"10.1016\/j.jtos.2021.05.004_bib68","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archopht.1990.01070060068051","article-title":"Effects of vasocon-A in the allergen challenge model of acute allergic conjunctivitis","volume":"108","author":"Abelson","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0091-6749(94)90081-7","article-title":"Conjunctivitis medicamentosa","volume":"94","author":"Spector","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib70","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/112067210901900119","article-title":"Abuse of vasoconstrictive eyedrops mimicking an ocular pemphigoid","volume":"19","author":"Tappeiner","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200911-1701OC","article-title":"Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion","volume":"182","author":"Vaidyanathan","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtos.2021.05.004_bib72","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0031-6997(24)01495-9","article-title":"Vascular adrenoceptors: an update","volume":"53","author":"Guimar\u00e3es","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jtos.2021.05.004_bib73","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archopht.1997.01100150036004","article-title":"Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants","volume":"115","author":"Soparhar","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib74","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/02713683.2017.1381269","article-title":"Evaluation of efficacy and safety of brimonidine tartrate ophthalmic solution, 0.025% for treatment of ocular redness","volume":"43","author":"Torkildsen","year":"2018","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cxo.12846","article-title":"Low-dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials","volume":"102","author":"Ackerman","year":"2019","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.jtos.2021.05.004_bib77","article-title":"Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis","volume":"2015","author":"Castillo","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtos.2021.05.004_bib78","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1517\/14656566.2015.1040760","article-title":"Advances in pharmacotherapy for allergic conjunctivitis","volume":"16","author":"Abelson","year":"2015","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jtos.2021.05.004_bib79","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1089\/jop.2013.0161","article-title":"The anti-inflammatory effects of therapies for ocular allergy","volume":"29","author":"Mantelli","year":"2013","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib80","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11882-011-0188-5","article-title":"Antihistamines in ocular allergy: are they all created equal?","volume":"11","author":"Abelson","year":"2011","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jtos.2021.05.004_bib81","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/09273948.2018.1432764","article-title":"Alcaftadine 0.25% versus olopatadine 0.1% in preventing cedar pollen allergic conjunctivitis in Japan: a randomized study","volume":"27","author":"Nakatani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2021.05.004_bib82","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0002-9394(00)00947-8","article-title":"Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis","volume":"131","author":"Verin","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib83","first-page":"167","article-title":"Azelastine eye drops in the treatment of perennial allergic conjunctivitis","volume":"53","author":"Nazarov","year":"2003","journal-title":"Arzneimittel-Forschung\/Drug Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/JAA.S38671","article-title":"A multi-center evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model","author":"Ackerman","year":"2013","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jtos.2021.05.004_bib85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/187221311794474883","article-title":"Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis","volume":"5","author":"Mishra G","year":"2011","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.jtos.2021.05.004_bib86","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/ACI.0b013e328357d3ba","article-title":"Ophthalmic antihistamines and H 1-H 4 receptors","volume":"12","author":"Wade","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib87","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/jop.2010.0153","article-title":"Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis","volume":"27","author":"Bohets","year":"2011","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib88","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1358\/dot.2011.47.12.1709243","article-title":"ALCAftadine: a topical antihistamine for use in allergic conjunctivitis","volume":"47","author":"Namdar","year":"2011","journal-title":"Drugs Today"},{"key":"10.1016\/j.jtos.2021.05.004_bib89","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jfma.2011.09.004","article-title":"A double-masked study to compare the efficacy and safety of topical cromolyn for the treatment of allergic conjunctivitis","volume":"110","author":"lin","year":"2011","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jtos.2021.05.004_bib90","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2500\/aap.2013.34.3695","article-title":"An algorithm for the management of allergic conjunctivitis","volume":"35","author":"Bielory","year":"2013","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jtos.2021.05.004_bib91","first-page":"75","article-title":"Opticrom in the management of blepharitis","volume":"211","author":"Collum","year":"1984","journal-title":"Bull La Soc Belge d\"ophtalmologie"},{"key":"10.1016\/j.jtos.2021.05.004_bib92","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.83.2.180","article-title":"Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis","volume":"83","author":"Tabbara","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib93","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/14656566.2017.1346085","article-title":"Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis","volume":"18","author":"Gonzalez-Estrada","year":"2017","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.jtos.2021.05.004_bib94","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2147\/OPTH.S13479","article-title":"Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis","volume":"4","author":"Williams","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1081-1206(10)62814-1","article-title":"Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model","volume":"81","author":"Abelson","year":"1998","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib96","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0002-9394(98)00044-0","article-title":"Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity","volume":"125","author":"Abelson","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib97","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0420.1999.tb01174.x","article-title":"Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model","volume":"77","author":"Deschenes","year":"1999","journal-title":"Acta Ophthalmol Scand Suppl"},{"key":"10.1016\/j.jtos.2021.05.004_bib98","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1034\/j.1600-0420.2003.00079.x","article-title":"Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis","volume":"81","author":"Yaylali","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jtos.2021.05.004_bib99","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/09273948.2016.1158282","article-title":"Topical olopatadine in the treatment of allergic conjunctivitis: a systematic review and meta-analysis","volume":"25","author":"Kam","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2021.05.004_bib100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1081-1206(10)62292-2","article-title":"Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms","volume":"86","author":"Lanier","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib101","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/OPTH.S131830","article-title":"Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis","volume":"11","author":"McLaurin","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib102","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s12325-014-0156-2","article-title":"Efficacy of olopatadine versus epinastine for treating allergic conjunctivitis caused by Japanese cedar pollen: a double-blind randomized controlled trial","volume":"31","author":"Fukushima","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2021.05.004_bib103","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/ACI.0b013e328364d86a","article-title":"Immunomodulators for conjunctivitis","volume":"13","author":"Pacharn","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jfo.2013.02.007","article-title":"Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis","volume":"37","author":"Mortemousque","year":"2014","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/ICL.0b013e3181e4bb40","article-title":"Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis","volume":"36","author":"Khurana","year":"2010","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2021.05.004_bib106","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtos.2021.05.004_bib107","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1755-3768.2008.01265.x","article-title":"Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial","volume":"87","author":"Borazan","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2015.09.029","article-title":"Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial","volume":"123","author":"Pinto-Fraga","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2021.05.004_bib109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/jop.1998.14.533","article-title":"The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate","volume":"14","author":"Abelson","year":"1998","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib110","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","article-title":"A randomized, double-masked, placebo-controlled, multi-center comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance","volume":"138","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib111","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1755-3768.2011.02272.x","article-title":"Management of seasonal allergic conjunctivitis: guide to therapy","volume":"90","author":"Bielory","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib112","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00003226-200207000-00008","article-title":"Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis","volume":"21","author":"Leonardi","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2021.05.004_bib113","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","article-title":"Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome","volume":"106","author":"Marsh","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2021.05.004_bib114","first-page":"875","article-title":"Non-steroidal anti-inflammatory drugs: current trends in pharmacology and therapeutics","volume":"63","author":"Blaho","year":"1992","journal-title":"J Am Optom Assoc"},{"key":"10.1016\/j.jtos.2021.05.004_bib115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal anti-inflammatory drugs in ophthalmology","volume":"55","author":"Kim","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib116","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/030006057800600213","article-title":"Tanderil \u00ae\/Chloramphenicol eye ointment in the treatment of the \u201cred eye\u201d seen in general practice","volume":"6","author":"Rushford","year":"1978","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib117","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0039-6257(93)90038-9","article-title":"Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis","volume":"38","author":"Ballas","year":"1993","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/jop.1998.14.137","article-title":"A multi-center comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis","volume":"14","author":"Tauber","year":"1998","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib119","first-page":"177","article-title":"Topical ketorolac 0.5% Solution for the treatment of vernal keratoconjunctivitis","volume":"45","author":"Sharma","year":"1997","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00417-002-0612-6","article-title":"Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis","volume":"241","author":"D'Angelo","year":"2003","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib121","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.1995.11.361","article-title":"Safety and efficacy of diclofenac sodium 0.1% ophthalmic solution in acute seasonal allergic conjunctivitis","volume":"11","author":"Laibovitz","year":"1995","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib122","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10384-004-0127-2","article-title":"Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis","volume":"48","author":"Miyake-Kashima","year":"2004","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib123","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1097\/IJG.0000000000000227","article-title":"Time course of prostaglandin analog-related conjunctival hyperemia and the effect of a nonsteroidal anti-inflammatory ophthalmic solution","volume":"25","author":"Sakata","year":"2016","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2021.05.004_bib124","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00003226-200203000-00006","article-title":"Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis","volume":"21","author":"Perry","year":"2002","journal-title":"Cornea"},{"key":"10.1016\/j.jtos.2021.05.004_bib125","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multi-center randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2021.05.004_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2021.05.004_bib127","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1442-9071.2006.01221.x","article-title":"Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions","volume":"34","author":"Fukushima","year":"2006","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","article-title":"A randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study","volume":"126","author":"Leonardi","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2021.05.004_bib129","doi-asserted-by":"crossref","first-page":"507","DOI":"10.11622\/smedj.2015161","article-title":"Efficacy and safety of topical cyclosporine a 0.05% in vernal keratoconjunctivitis","volume":"57","author":"Y\u00fccel","year":"2016","journal-title":"Singap Med J"},{"key":"10.1016\/j.jtos.2021.05.004_bib130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ICL.0000000000000055","article-title":"Topical cyclosporine a 1% for the treatment of chronic ocular surface inflammation","volume":"40","author":"Ragam","year":"2014","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2021.05.004_bib131","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":"Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2021.05.004_bib132","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1600-0420.1999.770217.x","article-title":"Toxicological evaluation of cyclosporine eyedrops","volume":"77","author":"Knagenhjelm","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jtos.2021.05.004_bib133","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2147\/OPTH.S150587","article-title":"Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops","volume":"12","author":"Ng","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib134","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0008-4182(05)80116-4","article-title":"Effects of a 0.9% sodium chloride ophthalmic solution on the ocular surface of symptomatic contact lens wearers","volume":"40","author":"Barabino","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/OPTH.S75297","article-title":"An evaluation of retaineTM ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye","volume":"9","author":"Ousler","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib136","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ICL.0b013e3181a2c986","article-title":"An investigation of the efficacy of a novel ocular lubricant","volume":"35","author":"Dumbleton","year":"2009","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.jtos.2021.05.004_bib137","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2013.08.007","article-title":"Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis","volume":"121","author":"Bilkhu","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2021.05.004_bib138","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/164_2016_73","article-title":"Ocular pharmacology of tear film, dry eye, and allergic conjunctivitis","volume":"242","author":"Gulati","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib139","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2147\/CIA.S98102","article-title":"Oral supplementation with a nutraceutical formulation containing omega-3 fatty acids, vitamins, minerals, and antioxidants in a large series of patients with dry eye symptoms: results of a prospective study","volume":"11","author":"Gatell-Tortajada","year":"2016","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jtos.2021.05.004_bib140","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.3945\/jn.109.118901","article-title":"Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye","volume":"140","author":"Larmo","year":"2010","journal-title":"J Nutr"},{"key":"10.1016\/j.jtos.2021.05.004_bib141","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/aos.12629","article-title":"A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial","volume":"93","author":"Garcia-Medina","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib142","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1709691","article-title":"n\u22123 Fatty acid supplementation for the treatment of dry eye disease","volume":"378","author":"Asbell","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtos.2021.05.004_bib143","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00126839-200506060-00005","article-title":"Preclinical pharmacology of bilastine, a new selective histamine H 1 receptor antagonist: receptor selectivity and in Vitro antihistaminic activity","volume":"6","author":"Corc\u00f3stegui","year":"2005","journal-title":"Drugs R"},{"issue":"Suppl 3","key":"10.1016\/j.jtos.2021.05.004_bib144","first-page":"24","article-title":"Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis","volume":"21","author":"Bartra","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1398-9995.2008.01813.x","article-title":"Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients","volume":"64","author":"Bachert","year":"2009","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib146","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2222.2009.03257.x","article-title":"Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study","author":"Kuna","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jtos.2021.05.004_bib147","doi-asserted-by":"crossref","DOI":"10.1007\/s00011-009-0117-4","article-title":"The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber","author":"Horak","year":"2010","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib148","series-title":"A study evaluating bilastine ophthalmic solution 0.6% in the conjunctival allergen challenge (Ora-CAC\u00ae) model","author":"NCT03479307","year":"2018"},{"key":"10.1016\/j.jtos.2021.05.004_bib149","doi-asserted-by":"crossref","DOI":"10.1124\/mol.107.038794","article-title":"Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?","author":"Newton","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib150","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/jop.2010.0177","article-title":"Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases","volume":"27","author":"Kato","year":"2011","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2021.05.004_bib151","first-page":"745","article-title":"Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infltrating the conjunctiva in late-phase experimental ocular allergy","volume":"8","author":"Baiula","year":"2014","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jtos.2021.05.004_bib152","series-title":"Mapracorat ophthalmic formulation in subjects with allergic conjunctivitis - Tabular View - ClinicalTrials.gov","author":"NCT01289431","year":"2011"},{"key":"10.1016\/j.jtos.2021.05.004_bib153","doi-asserted-by":"crossref","DOI":"10.1185\/03007995.2010.539502","article-title":"Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma","author":"Milgrom","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtos.2021.05.004_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib155","doi-asserted-by":"crossref","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","author":"Casale","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jtos.2021.05.004_bib156","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.04.2010.2919","article-title":"Omalizumab for severe atopic keratoconjunctivitis","volume":"2010","author":"Taill\u00e9","year":"2010","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jtos.2021.05.004_bib157","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","article-title":"Omalizumab treatment of vernal keratoconjunctivitis","volume":"134","author":"Heffler","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib158","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jaapos.2012.12.153","article-title":"Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab","volume":"17","author":"De Klerk","year":"2013","journal-title":"J AAPOS"},{"key":"10.1016\/j.jtos.2021.05.004_bib159","doi-asserted-by":"crossref","DOI":"10.1039\/b717398a","article-title":"Recent advances in urocanic acid photochemistry, photobiology and photoimmunology","author":"Gibbs","year":"2008","journal-title":"Photochem Photobiol Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib160","doi-asserted-by":"crossref","DOI":"10.1111\/aos.12651","article-title":"A randomized phase i clinical study of cis-urocanic acid eye drops in healthy adult subjects","author":"Jauhonen","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib161","doi-asserted-by":"crossref","DOI":"10.1007\/s00417-017-3781-z","article-title":"Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model","author":"Jauhonen","year":"2017","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib162","series-title":"Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA eye drops in Adult Healthy Volunteers (phase I) - No study results posted - ClinicalTrials.gov","author":"NCT01476332","year":"2012"},{"key":"10.1016\/j.jtos.2021.05.004_bib163","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1111\/bph.14458","article-title":"DS-70, a novel and potent \u03b14 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in Guinea pigs","volume":"175","author":"Dattoli","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib164","article-title":"Promising therapeutic drug delivery systems for glaucoma: a comprehensive review","volume":"12","author":"Singh","year":"2020","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib165","doi-asserted-by":"crossref","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","author":"Agrahari","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/S0074-7696(03)31001-0","article-title":"Role of mucins in the Function of the corneal and conjunctival epithelia","author":"Gipson","year":"2003","journal-title":"Int Rev Cytol"},{"key":"10.1016\/j.jtos.2021.05.004_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2005.07.005","article-title":"The use of mucoadhesive polymers in ocular drug delivery","author":"Ludwig","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtos.2021.05.004_bib168","doi-asserted-by":"crossref","DOI":"10.15171\/apb.2016.046","article-title":"Comparison of different nanosuspensions as potential ophthalmic delivery systems for ketotifen fumarate","author":"Soltani","year":"2016","journal-title":"Adv Pharmaceut Bull"},{"key":"10.1016\/j.jtos.2021.05.004_bib169","article-title":"Design of eudragit R.L. nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate","author":"Soltani","year":"2016","journal-title":"Iran J Basic Med Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib170","article-title":"Optimization of subconjunctival biodegradable microfilms for sustained drug delivery to the anterior segment in a small animal model","author":"Liu","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib171","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/20\/22\/225108","article-title":"Hybrid polymeric hydrogels for ocular drug delivery: Nanoparticulate systems from copolymers of acrylic acid-functionalized chitosan and N-isopropylacrylamide or 2-hydroxyethyl methacrylate","author":"Barbu","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jtos.2021.05.004_bib172","doi-asserted-by":"crossref","DOI":"10.2174\/156720112801323125","article-title":"Controlled and continuous release ocular drug delivery systems: pros and cons","author":"Abdelkader","year":"2012","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.jtos.2021.05.004_bib173","article-title":"A biodegradable, sustained-released, tacrolimus microfilm drug delivery system for the management of allergic conjunctivitis in a mouse model","author":"Liu","year":"2018","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib174","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1515\/med-2017-0034","article-title":"Model for studying anti- allergic drugs for allergic conjunctivitis in animals","volume":"12","author":"Nakazawa","year":"2017","journal-title":"Open Med"},{"key":"10.1016\/j.jtos.2021.05.004_bib175","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1046\/j.1365-2222.2003.01698.x","article-title":"Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models","volume":"33","author":"Sengoku","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jtos.2021.05.004_bib176","doi-asserted-by":"crossref","unstructured":"Fukushima A, Tomita T. Image analyses of the kinetic changes of conjunctival hyperemia in histamine-induced conjunctivitis in Guinea pigs. Cornea n.d.;28:694-698. doi:10.1097\/ICO.0b013e3181a18acd.","DOI":"10.1097\/ICO.0b013e3181a18acd"},{"key":"10.1016\/j.jtos.2021.05.004_bib177","first-page":"340","article-title":"Automated measurement of bulbar redness","volume":"43","author":"Fieguth","year":"2002","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib178","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1167\/iovs.13-12217","article-title":"The ocular redness index: a novel automated method for measuring ocular injection","volume":"54","author":"Amparo","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib179","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1167\/iovs.12-10678","article-title":"New clinical grading scales and objective measurement for conjunctival injection","volume":"54","author":"Hwang","year":"2013","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib180","doi-asserted-by":"crossref","DOI":"10.3109\/02713689508995816","article-title":"Automatic quantitative measurement of ocular hyperemia","author":"Willingham","year":"1995","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib181","first-page":"182","article-title":"Autoimmunity in dry eye is due to resistance of Th17 to treg suppression","author":"Chauhan","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jtos.2021.05.004_bib182","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaut.2016.11.003","article-title":"Interleukin-7 and -15 maintain pathogenic memory Th17 cells in autoimmunity","volume":"77","author":"Chen","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jtos.2021.05.004_bib183","doi-asserted-by":"crossref","DOI":"10.1186\/1824-7288-39-18","article-title":"Allergic conjunctivitis: a comprehensive review of the literature","volume":"39","author":"La Rosa","year":"2013","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.jtos.2021.05.004_bib184","first-page":"198","article-title":"Aimal models of high-risk corneal transplantation: a comprehensive review","author":"Singh","year":"2020","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jtos.2021.05.004_bib185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091282","article-title":"Oleanolic acid controls allergic and inflammatory responses in experimental allergic conjunctivitis","volume":"9","author":"Co\u0155dova","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jtos.2021.05.004_bib186","article-title":"Effects of exposure to ozone on the ocular surface in an experimental model of allergic conjunctivitis","volume":"12","author":"Lee","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.jtos.2021.05.004_bib187","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejphar.2016.06.014","article-title":"Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa","volume":"788","author":"Trzeciecka","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jtos.2021.05.004_bib188","article-title":"Animal models of bacterial Keratitis","author":"Marquart","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.jtos.2021.05.004_bib189","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens7010009","article-title":"The pathogenesis of staphylococcus aureus eye infections","author":"O'Callaghan","year":"2018","journal-title":"Pathogens"},{"key":"10.1016\/j.jtos.2021.05.004_bib190","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.02-0656","article-title":"A new topical model of Staphylococcus corneal infection in the mouse","author":"Girgis","year":"2003","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2021.05.004_bib191","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2009.4254.x","article-title":"Animal models for the treatment of bacterial keratitis","volume":"87","author":"Kowalski","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib199","doi-asserted-by":"crossref","first-page":"598.e1","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib200","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10384-016-0426-4","article-title":"Association between glaucoma eye drops and hyperemia","volume":"60","author":"Yanagi","year":"2016","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jtos.2021.05.004_bib201","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2016.10.003","article-title":"The intriguing role of neuropeptides at the ocular surface","volume":"15","author":"Sabatino","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2021.05.004_bib202","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jtos.2019.02.012","article-title":"Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review","volume":"17","author":"Holland","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2021.05.004_bib203","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/ACI.0b013e32830e6b17","article-title":"The role of neuromediators in ocular allergy","volume":"8","author":"Micera","year":"2008","journal-title":"Curr Opin Allergy Clin Immunol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012421000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012421000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:44:54Z","timestamp":1761540294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012421000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":195,"alternative-id":["S1542012421000434"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2021.05.004","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular redness \u2013 II: Progress in development of therapeutics for the management of conjunctival hyperemia","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}